Tenofovir Alafenamide

COMPOSITION:

Each film-coated tablet contains Tenofovir alafenamide fumarate 28 mg equivalent to Tenofovir alafenamide……………………………………25mg.

INDICATIONS:

LuciTeno is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease.

DOSAGE AND USE:

• Recommended dosage: 25 mg (one tablet) taken orally once daily with food.

• Renal Impairment: LuciTeno is not recommended in patients with estimated creatinine clearance below 15 mL per minute who are not receiving chronic hemodialysis. In patients on chronic hemodialysis, on hemodialysis days, administer LuciTeno after hemodialysis.

• Hepatic Impairment: LuciTeno is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNINGS:

Keep medicine out of reach of Children. Do not administer LuciTeno during Pregnancy and Lactation.